News Sobi starts rolling FDA filing for chronic gout drug Sweden’s Sobi has kicked off a rolling biologics license application in the US for SEL-212, vying to become a new option for patients with refractory chronic gout that doesn’t respond to cu
News FDA approves Ironwood's gout combination drug Good news for Ironwood, which forecast annual sales of up to $300m, despite black box kidney failure warning.
UK & Europe NICE says Otezla's bargain price offsets lower efficacy Otezla cheap and convenient, but less effective than rivals, says NICE.
News Janssen's RA candidate among hot topics at EULAR But attendees warned to expect "oceanic" weather.
News MSD stops trials of BTK inhibitor for blood cancers MSD has stopped development of BTK inhibitor nemtabrutinib, acquired via its $2.7bn takeover of ArQule, after trial results pointed to a safety issue.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.